Equillium Inc
Equillium Inc has a market capitalization of $163.76 million and a price-to-book ratio of 5.73, indicating that the market is valuing the company at a premium to its book value. The company's liquidity position is strong, with $30.28 million in cash and equivalents and a current ratio of 10.58, suggesting that it has ample short-term liquidity to cover its liabilities. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating that it is entirely equity-financed. The company's profitability metrics are negative, with a return on equity of -7.83% and a return on assets of -7.02%, reflecting a lack of profitability and operational efficiency. The company reported a net loss of $22.40 million and an operating loss of $23.63 million, with no revenue reported, indicating that it is in the early stages of commercialization or still in development. The company's operating cash flow is negative at -$22.75 million, and its free cash flow is also negative at -$22.33 million, suggesting that it is not generating positive cash flows from operations. Equillium Inc does not report revenue by segment or geographic region, so it is not possible to assess the concentration of its revenue across different business lines or geographic markets. The company's capital expenditures are minimal at -$48,000, indicating that it is not investing heavily in physical assets at this time. The company's growth trajectory is not yet defined, as it has not reported any revenue and is currently in a net loss position. Analysts have provided a mean price target of $7.14 and a median price target of $6.00, with a mean recommendation of 1.62, indicating a generally positive outlook from the analyst community. The company has four strong-buy ratings, three buy ratings, and one hold rating, suggesting that the majority of analysts see potential in the company's future performance. The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company has a low dilution potential, and no adjustments have been applied to its valuation metrics, indicating that there are no significant dilutive events on the horizon. There are no recent events or filings that have been disclosed in the provided data, so it is not possible to assess the company's recent performance or strategic direction based on public disclosures.
Business. Equillium Inc is a biotechnology company focused on the development of novel therapeutics for the treatment of autoimmune and inflammatory diseases.
Classification. Equillium Inc is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.
- Equillium Inc is a biotechnology company with no reported revenue and is currently in a net loss position.
- The company has a strong liquidity position with $30.28 million in cash and equivalents and a current ratio of 10.58.
- The company's profitability metrics are negative, with a return on equity of -7.83% and a return on assets of -7.02%.
- Analysts have provided a generally positive outlook, with a mean price target of $7.14 and a median price target of $6.00.
- The company has low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected.
- --
- # RATIONALES
- ```json
- No immediate filing-based liquidity or dilution flags were detected.